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Aspirin has lower antiplatelet activity in diabetic patients. Our aim is to study the roles of acute hyperglycemia and hyperlipidemia
onaspirinfunctionindiabetic subjectswithand withoutcardiovascular disease. Usingurinethromboxane (pg/mgcreatinine) and
VerifyNow (Aspirin Resistance Measures-ARU), we investigated diabetic subjects during a 2-hour glucose challenge (n = 49) or a
4-hour fat challenge (n = 11). All subjects were currently taking aspirin (81 or 325mg). After fat ingestion, urine thromboxane
increased in all subjects (Mean ± SE before: after) (1209±336: 1552±371, P = .01), while we noted a trend increase in VerifyNow
measures (408 ± 8: 431 ± 18, P = .1). The response to glucose ingestion was variable. Diabetic subjects with cardiac disease and
dyslipidemia increased thromboxane (1693 ± 364: 2799 ± 513, P<. 05) and VerifyNow (457.6 ± 22.3: 527.1 ± 25.8, P<. 05)
measures after glucose. We conclude that saturated fat ingestion increases in vivo thromboxane production despite aspirin therapy.
1.Introduction
Aspirin (ASA) is one of the most commonly used med-
ications worldwide. There is no debate that ASA reduces
mortality in secondary prevention of cardiovascular disease
(CVD), but an important question is why some patients
do not beneﬁt from ASA therapy. It was suggested that
diabetic patients not treated with aspirin therapy display
increased platelet reactivity, and that aspirin treatment in
diabetic patients is less eﬀective than aspirin treatment in
nondiabetic patients [1, 2]. This phenomenon is known
as aspirin resistance (ASA-R) [3]. ASA-R is not limited to
diabetes and is documented in subjects with cardiovascular
and kidney disease. Despite the absence of a current gold
standard to deﬁne ASA resistance [4], urine thrombox-
ane and VerifyNow point-of-care optical aggregometry are
clinically validated with cutoﬀ values that predict worse
CVD outcomes [5–7]. Urine thromboxane is a measure on
in vivo thromboxane production. We previously demon-
strated that platelets are activated after incubation with
increasing glucose concentrations in vitro [8]. Chronic
hyperglycemia and hyperlipidemia are associated with ASA-
R[ 9], but the role of acute hyperglycemia and hyperlipi-
demia on ASA function in vivo has not been deﬁned. In this
study, we investigated the eﬀects of acute glucose and fat
ingestion on aspirin function in diabetic subjects with and
without cardiovascular disease.
2.MaterialsandMethods
We studied 55 subjects with diabetes on ASA therapy for at
least 2 weeks prior to testing. Subjects reported fasting to
the Clinical and Translational Research Center (CATS) at 8
am. Blood was obtained on arrival and 1 hour after glucose
(n = 49) or 4 hours after fat ingestion (n = 11). Five subjects2 International Journal of Endocrinology
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Figure 1: The response of urine thromboxane after glucose or fat ingestion (a). Urine thromboxane response to glucose ingestion (n = 49)
(b). Urine thromboxane response to fat ingestion (n = 11). A more consistent increase in 11-dh-TxB2 was observed following the fat
challenge compared to the glucose challenge. 11-dh-TxB2 = Thromboxane.
did both the fat and glucose challenge on separate days.
The study was approved by our Institutional Review Board,
and all patients provided written informed consent prior to
testing. Clinical cardiovascular disease was deﬁned by prior
coronaryarterybypasssurgery(CABG),percutaneoustrans-
luminal angioplasty (PTCA), or thrombotic stroke. Patients
were older than 18 years of age. The study excluded subjects
if they met any of the following criteria: bleeding diathesis
or a history of gastrointestinal bleeding, hemorrhagic stroke,
illicit drug or alcohol abuse, coagulopathy, major surgery
within 6 weeks prior to study, platelet count <100,000/mm3,
hematocrit <25%, creatinine >4mg/dL, or current use of
nonsteroidal anti-inﬂammatory drugs, anticoagulants, or
antiplatelet drugs other than aspirin.
Blood and urine collection: after an overnight fast, blood
was collected from the antecubital vein into Vacutainer tubes
(Becton-Dickinson, Franklin Lakes, NJ) at 8 am to avoid a
potential eﬀect of circadian rhythm on platelet function. All
patients were instructed to take their prescribed morning
medications prior to blood draw. After collecting the ﬁrst
2-3mL of free ﬂowing blood for other measurements, the
tubes were ﬁlled to capacity and gently inverted 3 to 5
times to ensure complete mixing of the anticoagulant.
Tubes containing 3.2% sodium citrate (Greiner Bio-One
Vacuette North America, Inc., Monroe, NC) were collected
for VerifyNow measurements. Urine samples were collected
for measurements of 11-dh-TxB2 (Corgenix, Bloomﬁeld,
CO) and stored at −20◦C until analysis.
2.1. VerifyNow Aspirin Assay. VerifyNow (Accumetrics, CA)
isaturbidimetricopticaldetectionassaydesignedtomeasure
plateletaggregationthatisbasedupontheabilityofactivated
platelets to bind to ﬁbrinogen [6]. The cartridge contains a
lyophilized preparation of human ﬁbrinogen-coated beads,
arachidonic acid, preservative, and buﬀer. The ﬁbrinogen-
coated beads aggregate in whole blood in proportion to
the number of unblocked platelet GPIIb/IIIa receptors. The
instrument reports aggregation as aspirin resistance units
(ARUs). There is no signiﬁcant interaction between lipemia
and VerifyNow measures as per the manufacturer. The
coeﬃcientofvariancewas2.5%onrepeatedmeasureswithin
patients. The between-patient coeﬃcient of variance was
12.5% at baseline.
2.2. Urinary Thromboxane (11-dh-TxB2). AspirinWorks
(Corgenix Co.) is an enzyme-linked immunosorbent assay
(ELISA). In brief, assay buﬀer and urine were incubated
with a monoclonal antibody followed by the addition of an
11-dh-TxB2-alkaline phosphate tracer. Urinary 11-dh-TxB2
concentrations were determined by measuring colorimetry
at 405nm using an ELISA reader and expressed as pg/mg
Creatinine [1, 7]. The coeﬃcient of variance was 4% on
repeated measures within patients. The between-patient
coeﬃcient of variance was 14% at baseline.
2.3. Oral Glucose and Fat Meal. Forty-nine subjects ingested
a standard glucose solution (Trutol 75, NERL Diagnostics)
consisting of 75 grams of glucose. For the fat diet, 11 subjects
ingested a standardized test meal [10] that consisted, per
square meter of body surface area, of 175mL of heavy
whipped cream (Shamrock Farms, 99% fat). Of 700 calories
per square meter, 99% (70g) were derived from fat, <1% wasInternational Journal of Endocrinology 3
Table 1: Baseline measures.
Patient characteristic Diabetics (n = 56)
Gender (M/F) 28/28
ASA dose (81mg/325mg) 48/8
Prior CVD 8/58 (14%)
Smoking, n (%) 7/49 (14%)
Age (years) 59 ±1.5
BMI (kg/m2)3 7 ±3
Medication (%)
ACE inhibitors or ARB 36%
Statin 51%
Insulin 43%
Waist circumference (cm) 111 ±2
Systolic BP (mmHg) 130 ±2
Diastolic BP (mmHg) 78 ±1.2
11-dh-TxB2 (pg/mg creatinine) 1465 ±125
ASA-S (%) 64%
VerifyNow (ARU) 455 ±12
ASA-S (%) 82%
LDL (mg/dL) 105 ±5
HDL (mg/dL) 47 ±2
TG (mg/dL) 210 ±26
Creatinine (mg/dL) 0.8 ±0.04
HbA1c % 8.5 ±0.3
Fasting Glucose (mg/dL) 169 ±11
Duration of diabetes (years) 10.5 ±1
Values are presented in means ± SE.
11-dh-TxB2: Urine thromboxane, ARU: Aspirin resistance units, TG:
Triglyceride, LDL: Low density lipoproteins, HDL: High density lipopro-
tein, ASA-S: Aspirin sensitive, ARB: Angiotensin receptor blocker, ACE:
Angiotensin converting enzyme.
derived from carbohydrates (<1g), or from proteins (<1g).
The cholesterol content was 25mg, and the ratio of total
polyunsaturated to saturated fat was 0.06. We recorded ASA-
R measures at one and two hours after glucose ingestion, and
two and four hours after fat ingestion. We report the most
prominent changes that we noted at one hour after glucose
ingestion and four hours after lipid ingestion. We measured
weight, height, waist circumference, fasting lipids, HbA1c,
uric acid, serum creatinine in all subjects at baseline, and
glucose or triglycerides levels after ingestion of the glucose
or fat challenge, respectively.
2.4. Deﬁnitions
2.4.1. Aspirin Resistance. Aspirin resistance was deﬁned by
previously reported criteria: ≥550 ARU by VerifyNow [5]o r
≥1500pg 11-dh-TxB2/mg creatinine during treatment with
81mg or 325mg of daily aspirin [7]. We deﬁned apriori a
group of responders with change of at least 10% increase
(calculated as premeasure/postmeasure) in thromboxane
and VN response after glucose or fat challenge.
2.4.2. Statistical Analysis. Categorical variables were ex-
pressed as n (%) and continuous variables as mean ± SE.
Nonparametric data were log transformed. Kruskal Wallis
was used to analyze groups with nonparametric distribution.
A one-way analysis of variance (ANOVA) for repeated
measures was used to compare levels of platelet function
between and within diabetic and nondiabetic patients. An
unpaired t-test was used to compare the prevalence of
aspirin resistance between groups; P<. 05 was considered
statistically signiﬁcant. Linear regression was used to explain
the changes in measures of ASA-R to measures of glucose
or triglyceride after the challenge. All statistical calculations
were performed using SPSS software (Chicago, IL).
3. Results
Our study subjects were mostly Caucasian, middle-aged
adults. The majority of our diabetic subjects were obese
and had a history of hyperlipidemia, hypertension, and were
receiving medical treatment such as statins, beta-blockers,
andangiotensinconvertingenzymeinhibitorsforprevention
and treatment of CVD. Table 1 summarizes the baseline
measurements.
The response to glucose or fat challenge is summarized
in Table 2. Urine thromboxane was signiﬁcantly increased
in all 11 subjects after fat ingestion (P = .01). Subjects
demonstrated a variable response to the glucose ingestion
(Figure 1). We did not ﬁnd a correlation between the
changes in glucose or triglyceride and the changes in
11-dh-TxB2 or VN. Within subjects that underwent the
glucose challenge (n = 4 9 ) ,w eh a dam i x e dr e s p o n s e
to glucose ingestion (Figure 1(a)). We deﬁned a group of
subjects with at least 10% increase (calculated as premea-
sure/postmeasure) in thromboxane and VN response after
glucose challenge (responders) and compared their proﬁles
to subjects that did not change their measures of ASA-
R after the glucose challenge, using an independent t-test.
In this analysis, 13 subjects did not change their 11-dh-
TxB2 measures, while 19 increased it by more than 10%.
For VN measures, 14 subjects did not change their ASA-
R measure, while 10 subjects had an increased response.
We did not analyze the data from subjects that had a
decrease in TxB2 or VN after the glucose ingestion. We
log transformed the data to account for nonparametric
distribution. As demonstrated in Table 3,s u b j e c t sw i t ha n
increased response to glucose were more aspirin resistant per
11-dh-TxB2 criteria at baseline compared to subjects where
ASA-R measures did not change. Subjects with elevated 11-
dh-TxB2 or VN measures in response to glucose tended
to have a prior history of CVD, greater LDL cholesterol,
and longer duration of diabetes. There was no correlation
between the change in plasma glucose before and after
glucose ingestion and measures of aspirin resistance. After
glucose ingestion, two subjects were deﬁned as aspirin
resistant per the urine thromboxane criteria and three
subjects per VN criteria. After fat ingestion, one subject
developed ASA-R using 11-dh-TxB2 cutoﬀ values and one
subjectusing VN values. Therewas no signiﬁcant correlation4 International Journal of Endocrinology
Table 2: Response to glucose or fat challenge.
Glucose challenge (n = 49) Fat challenge (n = 11)
Pre Post P
value Pre Post P
value
Glucose(mg/dL) 169 ±11 289 ±16 <.001 Triglyceride (mg/dL) 210 ± 26 369 ±118 <.001
11-dh-TxB2 (pg/mg
creatinine) 1538 ±131 1806 ±247 .16 11-dh-TxB2 (pg/mg
creatinine) 1209 ±336 1552 ± 371 .01
VerifyNow (ARU) 461 ±12 453 ±13 .4 VerifyNow (ARU) 408 ±8 431 ±18 .1
Values are presented in means ± SE.
Table 3: Response to glucose ingestion.
11-dh-TxB2 (pg/mg of creatinine) VN (ARU)
Nonresponders (n = 13) Responders (n = 19) Nonresponders (n = 14) Responders (n = 10)
Pre-Glucose % of ASA-R 942 ± 117 1693 ± 364† 430.4 ±18.5 457.6 ±22.3
15 55 7 10
Post-Glucose % ASA-R 954.1 ± 122 2799 ± 513†‡ 428.5 ± 18.1 527.1 ± 25.8‡
15 63 7 33
CVD (n)1 4 † 04 †
Duration of diabetes 6.3 ± 1.7 8.4 ± 1.7 4.9 ± 1.4 11.1 ± 2.3†
LDL (mg/dL) 102 ± 8.6 126 ± 8.3† 105 ± 9.4 121 ± 11.6
Responders were deﬁned by more than 10% increase in ASA-R measures after glucose ingestion. ASA-R: aspirin resistant, ASA-S: aspirin sensitive, CVD:
cardiovascular disease.
Data are presented as means ± SE. The following group comparisons denote P<. 05. †Non-responders: Responders, ‡Pre: Post.
between the change in 11-dh-TxB2 / VN after glucose or fat
ingestion.
4. Discussion
This is the ﬁrst study to demonstrate that acute ingestion of
saturated fat consistently increases in vivo thromboxane pro-
duction, leading to a state of ASA-R. The lack of signiﬁcance
related to the measure of platelet function (VN) highlights
that the fat load may have increased production/excretion
of 11-dh-TxB2. Urinary thromboxane is not only a marker
of platelet activity, but also a marker of inﬂammation
and oxidative stress [11]. Urine thromboxane, as a global
index of thromboxane synthesis, originates from other blood
elements such as erythrocytes and monocytes and from
renal biosynthesis [12]. We previously reported that whole
blood incubation with increasing concentrations of glucose
increased platelet function by the upregulation of P-selectin
expression [8]. The current results suggest that the response
to glucose ingestion in vivo is more complex. Subjects
with chronic hyperglycemia, as assessed by the duration of
diabetes, dyslipidemia, and prior CVD, are likely to be ASA-
R in response to a high glucose load. The state of increased
thromboxane production and platelet activity after an acute
fat or glucose load may be a mechanism explaining the role
of a heavy meal as a trigger for acute myocardial infarction
[13, 14].
Although there is no gold standard for deﬁning ASA-R,
deﬁnitions based on urine 11-dh-TxB2 and VN assays have
cutoﬀ values that are clinically validated to predict worse
CVD outcomes. In a subanalysis of the Heart Outcomes
Prevention Evaluation (HOPE) study, the odds, over a
5-year period, of the composite outcome of myocardial
infarction, stroke, or CVD death in 976 ASA-treated patients
(488 who suﬀered myocardial infarction, stroke, or CVD
death and 488 sex- and age-matched controls) increased
with each increasing quartile urine thromboxane levels [7].
The antiplatelet eﬀect of aspirin measured by VerifyNow
correlated with adverse clinical events in stable patients with
CAD and is independent of known risk factors including
diabetes and prior MI [5]. The prevalence of ASA-R in
our study was 36% by urine 11-dh-TxB2, and 18% by
VN measures (Table 1). In comparison, the prevalence of
ASA resistance of diabetic subjects on 81mg of ASA in the
ASPECT study was 37% by urine 11-dh-TxB2, and 13% for
VN [1]. In another study [15] of subjects with CVD but not
diabetes,ASA-Rprevalencewas23%by11-dh-TxB2,and7%
by VN.
Possible mechanism(s) for the reduced ability of ASA
to suﬃciently protect against intravascular occlusions in
diabetes mellitus (DM) patients compliant with ASA ther-
apy include chronic hyperglycemia, hyperlipidemia, and
suboptimal ASA dosing, particularly in relation to altered
platelet turnover in diabetic patients [16, 17]. The activating
role of chronic hyperlipidemia on platelet function was
demonstrated both in vivo [18]a n din vitro [19]. Friend
et al. [18] found that platelet responsiveness to aspirin is
reduced in patients with chronic hyperlipidemia. Davi et
al. [20]o b s e r v e de n h a n c e din vivo formation of the F2-
isoprostane 8-epi-PGF2a in chronic hyperlipidemia that cor-
related with enhanced urine 11-dh-TxB2 production. This
provides an aspirin-insensitive mechanism possibly linking
lipid peroxidation to ampliﬁcation of platelet activation.International Journal of Endocrinology 5
Moreover, platelet responsiveness to ASA improves after
statin therapy [21]. Alternatively, oxidized LDL and oxidized
choline glycerophospholipids induce platelet activation and
thrombosis in fat fed mice through platelet CD36 [19]. The
molecular mechanisms explaining platelet response to acute
glucoseloadsmight be morecomplex.We suggestthatrather
than acute hyperglycemia per se, it is the mishandling of
hyperglycemia and resulting libration of oxygen-free radicals
[22] in subjects with chronic diabetes, dyslipidemia, and
prior cardiovascular disease leading to increased platelet
activation and thromboxane production.
The limitations of this study are the small sample size,
the absence of a control group, and a CVD cohort without
diabetes. The acute response to glucose or fat ingestion
may not reﬂect the chronic condition. Although we noted
a trend increase in VerifyNow after fat ingestion, the lack of
a signiﬁcant change is possibly related to our small cohort
size. The greater variability in the prechallenge 11-dh-TxB2
between the glucose and fat groups is likely related to the
small size of the fat challenge group.
5. Conclusion
In summary, our study indicates that saturated fat in the diet
increases in vivo thromboxane production. This highlights
the importance of low dietary saturated fat intake and
aggressive lipid management in diabetic patients on ASA
therapy.
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